EHA 2025: TG01 Shows Promise in KRAS-Mutated Myeloma

The ongoing Phase I/II TG01 study conducted at the Oslo Myeloma Center is investigating the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutations and either multiple myeloma or high-risk smoldering multiple myeloma.
At EHA 2025, Dr. Hanne Norseth presented data from the study. In this MEDtalk, she shares her insights into the results and discusses the potential of TG01 as a novel immunotherapeutic approach for this patient population.